Kolltan Approaching First IND Submission For RTK-Targeted Oncology Drug Candidate

Having raised about $75 million in venture funding since its 2007 inception, Kolltan Pharmaceuticals is getting closer to the clinic with novel oncology candidates targeting receptor tyrosine kinases.